Cargando…

Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence

BACKGROUND: Ganxianfang (GXF) formula as a traditional Chinese medicine (TCM) is used for liver fibrosis in clinical practice while its mechanism is unclear. The aim of this study is to explore the molecular mechanism of GXF against CCl(4)-induced liver fibrosis rats. METHODS: Detected the main comp...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zongyi, Xiang, Huanyu, Xiang, Dejuan, Xiao, Shuang, Xiang, Hongyan, Xiao, Jing, Ren, Hong, Hu, Peng, Liu, Huabao, Peng, Mingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855591/
https://www.ncbi.nlm.nih.gov/pubmed/35180857
http://dx.doi.org/10.1186/s13020-022-00579-7
_version_ 1784653683952189440
author Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiang, Hongyan
Xiao, Jing
Ren, Hong
Hu, Peng
Liu, Huabao
Peng, Mingli
author_facet Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiang, Hongyan
Xiao, Jing
Ren, Hong
Hu, Peng
Liu, Huabao
Peng, Mingli
author_sort Liu, Zongyi
collection PubMed
description BACKGROUND: Ganxianfang (GXF) formula as a traditional Chinese medicine (TCM) is used for liver fibrosis in clinical practice while its mechanism is unclear. The aim of this study is to explore the molecular mechanism of GXF against CCl(4)-induced liver fibrosis rats. METHODS: Detected the main compounds of GXF by UPLC-MS/MS. Evaluated the efficacy of GXF (1.58, 3.15, 4.73 g/kg/day) and Fuzheng Huayu (FZHY, positive control, 0.47 g/kg/day) through serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels and histopathological changes. Explored the underlying mechanisms by integrating our total liver RNA sequencing (RNA-seq) data with recent liver single-cell sequencing (scRNA-seq) studies. Verified potential pharmacodynamic substances of GXF by hepatic stellate cell (HSC)-T6 line. RESULTS: Main compounds were identified in GXF by UPLC-MS/MS, including baicalin, wogonoside and matrine etc. With GXF-high dose treatment, the elevation of ALT and AST induced by CCl(4) were significantly reduced, and the protective effect of GXF-high dose treatment was better than FZHY. Liver histopathological changes were alleviated by GXF-high dose treatment, the ISHAK scoring showed the incidence of liver cirrhosis (F5/F6) decreased from 76.5 to 55.6%. The results of liver hydroxyproline content were consistent with the histopathological changes. RNA-seq analysis revealed the differential genes (DEGs) were mainly enriched in ECM-receptor interaction and chemokine signaling pathway. GXF effectively inhibited collagen deposition and significantly downregulated CCL2 to inhibit the recruitment of macrophages in liver tissue. Integrating scRNA-seq data revealed that GXF effectively inhibited the expansion of scar-associated Trem2(+)CD9(+) macrophages subpopulation and PDGFRα(+)PDGFRβ(+) scar-producing myofibroblasts in the damaged liver, and remodeled the fibrotic niche via regulation of ligand-receptor interactions including TGFβ/EGFR, PDGFB/PDGFRα, and TNFSF12/TNFRSF12a signaling. In vitro experiments demonstrated that baicalin, matrine and hesperidin in GXF inhibited the activation of hepatic stellate cells. CONCLUSIONS: This study clarified the potential anti-fibrotic effects and molecular mechanism of GXF in CCl(4)-induced liver fibrosis rats, which deserves further promotion and application. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00579-7.
format Online
Article
Text
id pubmed-8855591
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88555912022-02-23 Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence Liu, Zongyi Xiang, Huanyu Xiang, Dejuan Xiao, Shuang Xiang, Hongyan Xiao, Jing Ren, Hong Hu, Peng Liu, Huabao Peng, Mingli Chin Med Research BACKGROUND: Ganxianfang (GXF) formula as a traditional Chinese medicine (TCM) is used for liver fibrosis in clinical practice while its mechanism is unclear. The aim of this study is to explore the molecular mechanism of GXF against CCl(4)-induced liver fibrosis rats. METHODS: Detected the main compounds of GXF by UPLC-MS/MS. Evaluated the efficacy of GXF (1.58, 3.15, 4.73 g/kg/day) and Fuzheng Huayu (FZHY, positive control, 0.47 g/kg/day) through serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) levels and histopathological changes. Explored the underlying mechanisms by integrating our total liver RNA sequencing (RNA-seq) data with recent liver single-cell sequencing (scRNA-seq) studies. Verified potential pharmacodynamic substances of GXF by hepatic stellate cell (HSC)-T6 line. RESULTS: Main compounds were identified in GXF by UPLC-MS/MS, including baicalin, wogonoside and matrine etc. With GXF-high dose treatment, the elevation of ALT and AST induced by CCl(4) were significantly reduced, and the protective effect of GXF-high dose treatment was better than FZHY. Liver histopathological changes were alleviated by GXF-high dose treatment, the ISHAK scoring showed the incidence of liver cirrhosis (F5/F6) decreased from 76.5 to 55.6%. The results of liver hydroxyproline content were consistent with the histopathological changes. RNA-seq analysis revealed the differential genes (DEGs) were mainly enriched in ECM-receptor interaction and chemokine signaling pathway. GXF effectively inhibited collagen deposition and significantly downregulated CCL2 to inhibit the recruitment of macrophages in liver tissue. Integrating scRNA-seq data revealed that GXF effectively inhibited the expansion of scar-associated Trem2(+)CD9(+) macrophages subpopulation and PDGFRα(+)PDGFRβ(+) scar-producing myofibroblasts in the damaged liver, and remodeled the fibrotic niche via regulation of ligand-receptor interactions including TGFβ/EGFR, PDGFB/PDGFRα, and TNFSF12/TNFRSF12a signaling. In vitro experiments demonstrated that baicalin, matrine and hesperidin in GXF inhibited the activation of hepatic stellate cells. CONCLUSIONS: This study clarified the potential anti-fibrotic effects and molecular mechanism of GXF in CCl(4)-induced liver fibrosis rats, which deserves further promotion and application. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-022-00579-7. BioMed Central 2022-02-18 /pmc/articles/PMC8855591/ /pubmed/35180857 http://dx.doi.org/10.1186/s13020-022-00579-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Zongyi
Xiang, Huanyu
Xiang, Dejuan
Xiao, Shuang
Xiang, Hongyan
Xiao, Jing
Ren, Hong
Hu, Peng
Liu, Huabao
Peng, Mingli
Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title_full Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title_fullStr Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title_full_unstemmed Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title_short Revealing potential anti-fibrotic mechanism of Ganxianfang formula based on RNA sequence
title_sort revealing potential anti-fibrotic mechanism of ganxianfang formula based on rna sequence
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855591/
https://www.ncbi.nlm.nih.gov/pubmed/35180857
http://dx.doi.org/10.1186/s13020-022-00579-7
work_keys_str_mv AT liuzongyi revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT xianghuanyu revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT xiangdejuan revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT xiaoshuang revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT xianghongyan revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT xiaojing revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT renhong revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT hupeng revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT liuhuabao revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence
AT pengmingli revealingpotentialantifibroticmechanismofganxianfangformulabasedonrnasequence